Receiving Adequate Iron is
Essential for My Good Health
The Only FDA Approved Drug Indicated to Replace Iron and Maintain Hemoglobin in Adult CKD-HD Patients
A New Way to
Treat Your Anemia
To receive a Triferic® patient
brochure in the mail please visit
our website at www.triferic.com
For more information,
ask your doctor or your clinic
about Triferic® today.
Like Us on Facebook:
www.facebook.com/triferic
Take
Action
IMPORTANT SAFETY INFORMATION
Warnings and Precautions Adverse Reactions
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have
been lifethreatening and fatal, have been reported in patients receiving parenteral iron products.
Patients may present with shock, clinically significant hypotension, loss of consciousness, and/
or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after
hemodialysis until clinically stable. Personnel and therapies should be immediately available
for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been
reported in 1 (0.3%) of 292 patients receiving Triferic® in two randomized clinical trials. Iron
status should be determined on pre-dialysis blood samples. Post dialysis serum iron parameters
may overestimate serum iron and transferrin saturation. The most common adverse reactions (>3% and at least 1% greater than placebo) in controlled
clinical studies include: headache, peripheral edema, asthenia, AV fistula thrombosis, urinary
tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle
spasms, pain in extremity, back pain, and dyspnea.
For full Safety and Prescribing Information please visit www.triferic.com.
Triferic® is a registered trademark of Rockwell Medical Inc.
www.triferic.com